Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BCG2-DTP3: Providing BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine to Improve Female Survival in Africa

NCT07005726 is registered in ClinicalTrials.gov with Bandim Health Project as lead sponsor.

NCT NCT07005726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07005726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BCG2-DTP3: Providing BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine to Improve Female Survival in Africa
Lead sponsor
Bandim Health Project
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
May 9, 2025
Completion date
July 31, 2030
Enrollment
6,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bcg, infant morbidity, infant mortality, non-specific effects of vaccines